These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9648714)

  • 1. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product.
    Stiehm ER; Casillas AM; Finkelstein JZ; Gallagher KT; Groncy PM; Kobayashi RH; Oleske JM; Roberts RL; Sandberg ET; Wakim ME
    J Allergy Clin Immunol; 1998 Jun; 101(6 Pt 1):848-9. PubMed ID: 9648714
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies.
    Meth MJ; Rosenthal DW; Bonagura VR
    Ann Allergy Asthma Immunol; 2010 Aug; 105(2):187-8. PubMed ID: 20674834
    [No Abstract]   [Full Text] [Related]  

  • 3. Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
    Rezaei N; Abolhassani H; Aghamohammadi A; Ochs HD
    Expert Rev Clin Immunol; 2011 May; 7(3):301-16. PubMed ID: 21595597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases.
    Bal K; Kałuzińska-Parzyszek I; Sobocińska A; Podlecka D; Jerzyńska J; Stelmach I
    Indian J Pediatr; 2015 Aug; 82(8):768-9. PubMed ID: 25786586
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation.
    Spitzer TR; Cottler-Fox M; Sullivan P; Lynch M; Tefft MC; Pickle LW; Cirenza E; Cahill R; Deeg HJ; Sacher R
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):123-6. PubMed ID: 1509292
    [No Abstract]   [Full Text] [Related]  

  • 7. [The use of human gamma globulin in the treatment of common variable immunodeficiency].
    de Gracia J; Vendrell M; Guarner L; Vidal R; Miravitlles M; Mayordomo C; Morell F
    Med Clin (Barc); 1995 Feb; 104(6):201-6. PubMed ID: 7534366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center.
    Ducruet T; Levasseur MC; Des Roches A; Kafal A; Dicaire R; Haddad E
    J Allergy Clin Immunol; 2013 Feb; 131(2):585-7.e1-3. PubMed ID: 23040368
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of certain immune deficient peripheral neuropathies with intravenous immunoglobulins].
    Pouget J
    Rev Prat; 1994 Nov; 44(18):2404-6. PubMed ID: 7855497
    [No Abstract]   [Full Text] [Related]  

  • 10. Specific antibody responses to diphtheria/tetanus revaccination in children evaluated for immunodeficiency.
    McCusker C; Somerville W; Grey V; Mazer B
    Ann Allergy Asthma Immunol; 1997 Aug; 79(2):145-50. PubMed ID: 9291419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of an intravenous immune globulin at various concentrations in 5% dextrose injection or sterile water for injection.
    Miller KB; Schenkein DP; Wasserman RL
    Clin Pharm; 1992 Jul; 11(7):628-31. PubMed ID: 1617914
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita.
    Tayal U; Burton J; Dash C; Wojnarowska F; Chapel H
    Clin Immunol; 2008 Dec; 129(3):518-9. PubMed ID: 18848500
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
    DiMario FJ
    Pediatrics; 2005 Jul; 116(1):226-8. PubMed ID: 15995056
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.
    Moore ML; Quinn JM
    Ann Allergy Asthma Immunol; 2008 Aug; 101(2):114-21; quiz 122-3, 178. PubMed ID: 18727465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical decisions in selecting an intravenous immunoglobulin product.
    Gelfand EW
    J Infus Nurs; 2005; 28(6):366-74. PubMed ID: 16304494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously.
    Desai SH; Chouksey A; Poll J; Berger M
    J Allergy Clin Immunol; 2009 Oct; 124(4):854-6. PubMed ID: 19767071
    [No Abstract]   [Full Text] [Related]  

  • 17. [The ESID Online Database for primary immunodeficiencies. First analyses with regard to Germany and Europe].
    Knerr V; Gathmann B; Eades-Perner AM; Kindle G; Grimbacher B
    Med Klin (Munich); 2008 Sep; 103(9):620-7. PubMed ID: 18813884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes.
    Bonilla FA
    Immunol Allergy Clin North Am; 2008 Nov; 28(4):803-19, ix. PubMed ID: 18940575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation.
    Nahirniak S; Hume HA
    Transfus Med Rev; 2010 Jan; 24 Suppl 1():S1-6. PubMed ID: 19962578
    [No Abstract]   [Full Text] [Related]  

  • 20. The immune system and intravenous administration of immune globulin. Part I, The immune system.
    Frey AM
    J Intraven Nurs; 1991; 14(5):315-30. PubMed ID: 1748915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.